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OBJECTIVE: With the progression of the renal insufﬁ-
ciency (RI) produced in the chronic allograft nephropa-
thy (CAN), the patients’ HRQoL worsens. The treatment
of the anemia associated to the RI with rh-EPO improves
the HRQoL. The objective of present study was to eval-
uate the HRQoL of kidney transplant patients with CAN
and anemia associated to the RI, and the effect of the
treatment with rh-EPO on the HRQoL. METHODS:
Prospective study of 24 kidney transplant patients with
RI caused by CAD and anemia who received rh-EPO to
treated the anemia. The hemoglobin target was 12gr/dL.
HRQoL was evaluated with the SF-36 Health Survey at
start treatment, 3 months later and at the end of follow-
up. SF-36 scores (8 dimensions, Physical-PCS and Mental
Component Summary-MCS) were standardized by age
and gender using the Spanish general population norms.
The “Effect Size” was also calculated for each dimension
and for summary scores. RESULTS: Hemoglobin statisti-
cally improved from start to third month (p < 0.01). SF-
36 scores of studied patients were worse than those of the
general population and that those of a transversal sample
of transplant patients with good renal function: PCS =
36.08 ± 12.83 vs. 48.68 ± 9.86; MCS = 47.16 ± 14.46
vs. 51.91 ± 10.25. Three SF-36 dimensions statistically
improved with the correction of anemia with the rh-EPO
treatment: Role Physical, Vitality and Mental Health. The
“Effect Size” was very small for Physical Functioning and
Social Functioning; small for General Health (0.28) and
PCS (0.23); moderate for Pain (0.41), Role Emotional
(0.39) and MCS (0.42); and large for Role Physical
(0.65), Vitality (0.81) and Mental Health (0.74). CON-
CLUSIONS: The poor HRQoL of kidney transplant
patients with CAN and anemia improves with the treat-
ment of the anemia with rh-EPO. The “Effect Size” for
this change in the HRQoL is moderate to large in major-
ity of HRQoL areas.
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OBJECTIVE: A great proportion (50–70%) of patients
with urinay incontinence (UI) do not ask for medical
advise. Symptom questionnaires may help in detecting the
UI. The objective of present study was to analize the psy-
chometric properties of the Spanish version of the ques-
tionnaire of UI symptoms “ICIQ-SF”. METHODS: A
total of 500 women who consulted at a UI-specialized
unit answered the questionnaire. Urodinamic study was
carried out, and sociodemographic and clinical data were
also collected including the symptoms expressed by the
patients. So there were two diagnostic tools for the assess-
ment: clinical and that of the urodinamic study. Feasibil-
ity, validity (comparing the scores between groups ac-
cording to both diagnostic methods, between goups of
different sort of UI and between groups of different sever-
ity degrees) and reliability (Cronbach’s alpha) were
assessed. Sensitivity (Se), speciﬁcity (Sp), positive (PPV)
and negative (NPV) predictive value with respect to clin-
ical diagnostic and that of the urodinamic study were also
calculated. RESULTS: Mean time of administration was
3 minutes. All patients answered all the items of the ICIQ-
SF. According to clinical diagnostic, patients with UI
showed higher score on the ICIQ-SF (11.6 ± 5.9) than
women without UI (4.5 ± 6.3) (p = 0.000). The same
occurs with the groups according to the urodinamic study
(11.1 ± 6.3 vs. 6.2 ± 6.5; p = 0.000). A higher severity
degree was associated to a higher score on the ICIQ-SF:
low degree (10.47 ± 5.61) vs. intermediate (12.4 ± 5.72)
vs high degree (13.61 ± 5.42). Cronbach’s alpha was 0.89.
The values of Se, Sp, PPV and NPV were 92.1%, 55.6%,
88.3% y 65.9% with respect to clinical diagnostic and
87.7%, 40.8%, 85.1% y 46.2% with respect to the uro-
dinamic study. CONCLUSIONS: This is the ﬁrst ques-
tionnaire design for diagnostic of UI validated in Spain.
The psychometric properties of the ICIQ-SF are satisfac-
tory and allow to recommend the use of the questionnaire
in the clinical practice.
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OBJECTIVE: To evaluate the HRQoL of the patients
who started RRT in our region during last 2 years (N =
284) following them along the time and searching for 
differences between elderly (≥65 years) and younger
patients. METHODS: Preliminary results of 66 patients
who remained in HD during one year are shown. Patients
excluded: a total of 8 because of cognitive deterioration.
An interview was carried out at three months from start
and one year later, using the SF-36 Health Survey, obtain-
ing a Physical (PCS) and a Mental (MCS) Component
Summary Scores, and the Physical Symptom scale (PSS)
of the Kidney Disease Questionnaire (KDQ). Sociodemo-
graphic and clinical data, Karnofsky Scale and a com-
orbidity index were also collected. SF-36 scores were
standardized using the Spanish general population norms.
RESULTS: Mean age = 66.8 ± 13.1 years (elderly 71.2%);
56% men. The main analytic and clinical parameters did
not change after one year: hemoglobin = 11.5 ± 1 versus
11.1 ± 1.5gr./dL.; Albumin = 3.6 ± 0.2 versus 3.6 ±
0.4gr./L.; Creatinine = 8.13 ± 2.39 versus 7.87 ±
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1.14mgr./dL. Karnofsky Scale score showed small varia-
tion: 70.3 ± 17.2 versus 72.5 ± 17.9 (n.s.). The mean score
of the PSS slightly increased after one year, indicating
improvement: 4.1 ± 1.3 versus 5.1 ± 2.1 (n.s.). The PCS
mean score of younger pts. (39.6 ± 15.0 ) was statistically
signiﬁcant worse than that of elderly (47.0 ± 8.6) at the
start (p < 0.05), but not at the end (44.4 ± 12.5) vs. (48.0
± 8.2) (n.s.). The PCS mean score of younger pts. was sta-
tistically signiﬁcant better after one year, indicating
improvement: 39.6 ± 15.0 vs. 44.4 ± 12.5 (p < 0.05). No
statistically signiﬁcant differences were found for MCS.
CONCLUSIONS: Elderly pts. showed lower loss of
HRQoL than younger pts. at start and one year later. The
HRQoL of elderly who started RRT remained stable after
one year of follow-up. The HRQoL of younger pts.
improved at one year of follow-up in physical aspects but
not in mental aspects.
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OBJECTIVES: The aim of this study is to evaluate 
cardiovascular risk factors in a group of early post-
menopausal women and the impact of low-dose hor-
monal replacement therapy on long term cardiovascular
risk replacement therapy (LD-HRT) (combined estradiol
1mg and noretisterone acetate 0.5mg). METHODS: Epi-
demiological, observational, prospective and multicenter
study on menopausal women who initiate LD-HRT with
Activelle® (combined estradiol 1mg and noretisterone
acetate 0.5mg) for six months. Anthropometric and
demographic characteristics, dietetic and hygienic habits,
gynecologic and obstetric history were recorded at the
beginning of treatment. Blood pressure was registered and
blood lipids analysis was performed at inclusion and at
the end of study. RESULTS: A total of 728 women were
enrolled, mean age 51.6 ± 4.3 years. Smokers 18.7%
(13.5 ± 7.8cig/day. Alcohol intake was greater than 30
g/day in 14% of women. After 6 months of treatment a
signiﬁcant improvement of blood lipid levels was
achieved: cholesterol decreased from 217 ± 36.24 to 207
± 40.54mg/dl (p < 0.001) y LDL decreased from 136.4 ±
39.31 to 126.4 ± 34.14mg/dl (p < 0.05), HDL increased
from 63.4 ± 19.49 to 64.4 ± 17.55mg/dl (p < 0.001),
triglyceride level decreased from 109.4 ± 51.74 to 106 ±
42.09mg/dl. Cardiovascular Disease Risk estimated to 10
years calculated by Framingham algorithm decreased
from 6.04 ± 3.87% to 5.34 ± 3.42% (p < 0.001) Rela-
tive risk factor decreased as well (from 1.35 ± 0.85 to
1.18 ± 0.72 (p < 0.001). CONCLUSIONS: LD-HRT
(Activelle®) treatment reduces blood pressure and blood
lipids levels. This positive effect on Cardiovascular Risk
factors implies a decrease on Cardiovascular Disease Risk
estimated to 10 years.
PWH2
EFFECTIVITY AND SAFETY OF ORAL LOW-
DOSE HORMONAL REPLACEMENT THERAPY
(COMBINED ESTRADIOL 1MG AND
NORETISTERONE 0.5MG) IN CLIMACTERIC
SYMPTOMS ON SPANISH POSTMENOPAUSAL
WOMEN
López JS1, Barnés E1, Mirada A2
1Pharma-Consult, Barcelona, Spain; 2Laboratorios Isdin,
Barcelona, Spain
OBJECTIVES: The aim of this study is to evaluate effec-
tivity and safety of low-dose hormonal replacement
therapy (LD-HRT) (combined estradiol 1mg and noretis-
terone acetate 0.5mg) in a group of early postmenopausal
women. METHODS: Epidemiological, observational,
prospective and multicenter study on menopausal women
who initiate LD-HRT Activelle® (combined estradiol 
1mg and noretisterone acetate 0.5mg). Anthropometric
and demographic characteristics, dietetic and hygienic
habits, gynecologic and obstetric history of patients 
were recorded. Menopausal symptoms were measured
using kupperman index (KI) scores: hemorrhages, vertigo,
fatigue, arthralgia, headache, palpitation, and pruritus.
After 6 months of treatment, menopausal symptoms were
registered. Lineal regression model was played to quan-
tify the response to treatment. RESULTS: A total of 728
women were enrolled, mean age 51.6 ± 4.3 years. 98.8%
of women improved their symptomatology, mean
decrease of KI score was 13.46 ± 7.73 points (from 19.98
± 8.53 to 6.41 ± 5.83). In 23.9% of women KI score
decrease was a value included in the interval between 18
and 24. Fulﬁllment of treatment was observed in 82.6%
of women. Adverse events were reported in 22 patients
(3% of total). Effectivity of treatment predicting factors
resulted: greater KI score, fulﬁllment of treatment, and
initiate treatment as a result of de novo diagnose of
menopause. (R2(ad) = 65.10%). CONCLUSIONS: LD-
HRT achieves a signiﬁcant improvement on climacteric
symptomatology. Tolerability of treatment is conﬁrmed
by the high rate of fulﬁllment and the low rate of adverse
events reported.
